- Home
- STAI vs CELU Comparison
STAI vs CELU Comparison
Compare STAI & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STAI
- CELU
- Stock Information
- Founded
- STAI 2011
- CELU 2016
- Country
- STAI United States
- CELU United States
- Employees
- STAI N/A
- CELU N/A
- Industry
- STAI
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- STAI
- CELU Health Care
- Exchange
- STAI Nasdaq
- CELU Nasdaq
- Market Cap
- STAI 36.3M
- CELU 42.2M
- IPO Year
- STAI N/A
- CELU N/A
- Fundamental
- Price
- STAI $1.96
- CELU $1.74
- Analyst Decision
- STAI
- CELU
- Analyst Count
- STAI 0
- CELU 0
- Target Price
- STAI N/A
- CELU N/A
- AVG Volume (30 Days)
- STAI 802.9K
- CELU 144.0K
- Earning Date
- STAI 01-01-0001
- CELU 12-06-2024
- Dividend Yield
- STAI N/A
- CELU N/A
- EPS Growth
- STAI N/A
- CELU N/A
- EPS
- STAI N/A
- CELU N/A
- Revenue
- STAI $522,166.00
- CELU $48,200,000.00
- Revenue This Year
- STAI N/A
- CELU N/A
- Revenue Next Year
- STAI N/A
- CELU $233.89
- P/E Ratio
- STAI N/A
- CELU N/A
- Revenue Growth
- STAI N/A
- CELU 225.94
- 52 Week Low
- STAI $1.23
- CELU $1.00
- 52 Week High
- STAI $12.19
- CELU $5.69
- Technical
- Relative Strength Index (RSI)
- STAI N/A
- CELU 50.73
- Support Level
- STAI N/A
- CELU $1.64
- Resistance Level
- STAI N/A
- CELU $2.40
- Average True Range (ATR)
- STAI 0.00
- CELU 0.21
- MACD
- STAI 0.00
- CELU 0.03
- Stochastic Oscillator
- STAI 0.00
- CELU 33.33
About STAI ScanTech AI Systems Inc. Common stock
ScanTech AI Systems Inc is developing and deploying security screening systems that protect travelers and other public members from criminals, terrorists, and other bad actors. It has developed a proprietary Computed Tomography scanning system that uses fixed-gantry technology to detect explosives, weapons, narcotics, and other contraband.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.